Provided by Tiger Fintech (Singapore) Pte. Ltd.

Jasper Therapeutics

2.28
+0.10004.59%
Post-market: 2.27-0.0100-0.44%19:12 EDT
Volume:241.65K
Turnover:546.42K
Market Cap:63.67M
PE:-0.38
High:2.33
Open:2.22
Low:2.20
Close:2.18
52wk High:26.05
52wk Low:2.16
Shares:27.92M
Float Shares:22.81M
Volume Ratio:0.51
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.0237
EPS(LYR):-4.8865
ROE:-146.87%
ROA:-73.30%
PB:2.71
PE(LYR):-0.47

Loading ...

Jasper Therapeutics Q2 EPS USD -1.74

THOMSON REUTERS
·
Aug 14

Jasper Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview

Reuters
·
Aug 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 08

BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Warner Music Group, GeneDx

Reuters
·
Jul 10

BUZZ-Jasper Therapeutics falls after halting clinical programs

Reuters
·
Jul 09

Press Release: Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway

Dow Jones
·
Jul 09

Jasper Therapeutics Is Maintained at Buy by BTIG

Dow Jones
·
Jul 08

BUZZ-U.S. STOCKS ON THE MOVE-U.S. Bancorp, IonQ, BlackRock

Reuters
·
Jul 08

HC Wainwright Adjusts Price Target on Jasper Therapeutics to $20 From $40, Maintains Buy Rating

MT Newswires Live
·
Jul 07

Sector Update: Health Care Stocks Lean Lower Premarket Monday

MT Newswires Live
·
Jul 07

BUZZ-Jasper Therapeutics plunges as co halts asthma trial due to drug lot issue

Reuters
·
Jul 07

Jasper Therapeutics Shares Plunge Premarket as Briquilimab Issues Upend Studies

Dow Jones
·
Jul 07

Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria

GlobeNewswire
·
Jul 07

Jasper Therapeutics Inc. Convened Annual Stockholders Meeting

Reuters
·
Jul 04

Jasper Therapeutics Unveils Presentation on KIT Inhibition and Briquilimab's Potential in Mast Cell Driven Diseases

Reuters
·
Jun 24

Jasper Therapeutics Shares Rise on Positive Data From Recent Study

Dow Jones
·
Jun 16

Jasper Therapeutics Unveils New Insights on Briquilimab's Efficacy in Mast Cell Mediated Diseases

Reuters
·
May 21

Jasper Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
May 14

RBC Adjusts Price Target on Jasper Therapeutics to $46 From $48, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
May 13

Jasper Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13